LAWSUITS FILED AGAINST EHTH, CONN and CTMX – JAKUBOWITZ LAW PURSUES SHAREHOLDERS CLAIMS

NEW YORK, NY / ACCESSWIRE / May 28, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

eHealth, Inc. (NASDAQ:EHTH)

CONTACT JAKUBOWITZ ABOUT EHTH:
https://claimyourloss.com/securities/ehealth-inc-loss-submission-form/?id=6975&from=1

Class Period: March 19, 2018 – April 7, 2020

Lead Plaintiff Deadline: June 8, 2020

The complaint alleges that eHealth, Inc. issued materially false and/or misleading information and/or failed to disclose: (1) its highly aggressive accounting and modeling assumptions; (2) its skyrocketing rate of member churn, resulting from eHealth's pursuit of low quality, lossmaking growth; (3) its reliance on direct response television advertising, which attracts an unprofitable, high churn enrollee; and (4) that as a result of the foregoing, defendants' public statements were materially false and misleading at all relevant times.

Conn's, Inc. (NASDAQ:CONN)

CONTACT JAKUBOWITZ ABOUT CONN:
https://claimyourloss.com/securities/conns-inc-loss-submission-form/?id=6975&from=1

Class Period: September 3, 2019 – December 9, 2019

Lead Plaintiff Deadline: July 14, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Conn's was experiencing an increase in first payment defaults and 60-plus day delinquencies; (2) as a result, Conn's was reasonably likely to record an increase to its provision for bad debts; (3) the Company made certain underwriting adjustments, including tightening its standards for new customers and online applicants; (4) as a result, the Company's same-store sales would be adversely impacted; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

CytomX Therapeutics, Inc. (NASDAQ:CTMX)

CONTACT JAKUBOWITZ ABOUT CTMX:
https://claimyourloss.com/securities/cytomx-therapeutics-inc-loss-submission-form/?id=6975&from=1

Class Period: May 17, 2018 – May 13, 2020

Lead Plaintiff Deadline: July 20, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) CytomX had downplayed issues with CX-072's efficacy observed in the PROCLAIM-CX-072 clinical program; (ii) CytomX had similarly downplayed issues with CX-2009's efficacy and safety observed in the PROCLAIM-CX-2009 clinical program; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE: Jakubowitz Law

ReleaseID: 591827